ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2247

Priority Research Topics for Vaccine Uptake Among Adults with Autoimmune Conditions

Shilpa Venkatachalam1, William Benjamin Nowell2, Shubhasree Banerjee3, Kelly Gavigan4, Laura Stradford2, Jennifer Gordon5, Lisa Emerich6, Hope Sullivan7, Ashira Blazer8, Brittany Banbury9, Vandana Dronadula1, Kimberly Weaver10, Angela Degrassi4, Peter Merkel3, Robert McBurney11, Mike Kappelman10, Jeffrey Curtis12 and Michael George3, 1Global Healthy Living Foundation, New York, NY, 2Global Healthy Living Foundation, Nyack, NY, 3University of Pennsylvania, Philadelphia, PA, 4Global Healthy Living Foundation, Upper Nyack, NY, 5Vasculitis Foundation, Philadelphia, 6iConquerMS, Waltham, MA, 7Inflammatory Bowel Disease (IBD) Partners, Chapel Hill, NC, 8Hospital for Special Surgery, New York, NY, 9NYU Langone, Fort Lee, NJ, 10School of Medicine, University of North Carolina (UNC), Chapel Hill, NC, 11Accelerated Cure Project for Multiple Sclerosis, Waltham, MA, 12University of Alabama at Birmingham, Hoover, AL

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Autoinflammatory diseases, health behaviors, immunology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: Patient Outcomes, Preferences, and Attitudes: Patient Priorities and Preferences: Interventions and Transformation

Session Type: Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Compared to the general population, adults living with autoimmune disease are at nearly twice the risk of vaccine-preventable infections, making this a high priority vaccination group. The objective of this study was to prioritize topics for future patient-centered research to reduce vaccine hesitancy and increase uptake of vaccines for conditions such as pneumococcal pneumonia, influenza, zoster, human papillomavirus, and SARS-CoV-2 among adults living with autoimmune conditions, as informed by a range of stakeholders in the autoimmune health community.

Methods: We convened a steering committee (SC) of clinicians and patients with representation from rheumatic diseases (PsA, RA, vasculitis), inflammatory bowel disease, and multiple sclerosis. Through literature review and iterative discussions, SC members identified 33 vaccine uptake/hesitancy research topics in four domains. A larger multistakeholder group including patients and patient advocates (Patients/Advocates); clinicians and researchers (Clinicians/Researchers); policy makers, regulators, and vaccine manufacturers (Other Stakeholders) was convened to conduct a modified online Delphi process with two rounds currently completed. In each round, group members rated each topic on a 9-point scale (1-3 = not important, 4-6 = important but not critical, 7-9 = critical) and could propose additional topics for inclusion in the next round. When completing round 2 (R2), participants were able to view their ratings from the previous round and view aggregate ratings from their respective stakeholder group before confirming or changing how they rated each topic. Frequency analysis and comparisons across the three stakeholder groups (Patients/Clinicians/Other) was conducted.

Results: A total of 34 stakeholders participated in both R1 and R2 of the Delphi to rate the 33 R1 and 34 R2 topics. Overall, six topics, representing at least one topic from each domain, were rated as critical by > 90% of stakeholders, including topics related to vaccine effectiveness in autoimmune disease, beliefs about safety, myths and misinformation, trust in the healthcare system, barriers to access, and vaccine safety profiles (Table 1). The Patient/Patient Advocate group unanimously rated three topics as critical: How myths or misinformation about vaccines affect vaccine uptake, How source of information about vaccines affects vaccine uptake, and How perceived transparency of information about vaccines affect vaccine uptake. The Researchers/Clinicians group unanimously rated How well a vaccine works for adults with autoimmune conditions as critical.

Conclusion: Topics identified as critical across stakeholder groups can inform future research efforts to decrease vaccine hesitancy and improve uptake of relevant vaccines for adults with autoimmune conditions, a high-priority group for vaccinations.

Supporting image 1

Table 1. Research Topics Rated as Critical for Vaccine Uptake Among Adults with Autoimmune Conditions


Disclosures: S. Venkatachalam, None; W. Nowell, Global Healthy Living Foundation, AbbVie Inc., Amgen, Eli Lilly; S. Banerjee, None; K. Gavigan, None; L. Stradford, Global Healthy Living Foundation; J. Gordon, None; L. Emerich, None; H. Sullivan, Merck/MSD; A. Blazer, None; B. Banbury, None; V. Dronadula, None; K. Weaver, None; A. Degrassi, None; P. Merkel, AbbVie, AstraZeneca, Boeringher-Ingelheim, Bristol-Myers Squibb, ChemoCentryx, Forbius, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Neutrolis, Takeda, CSL Behring, Dynacure, EMDSerono, Immagene, Jannsen, Kiniksa, Magenta, Novartis, Pfizer, Q32, Regeneron, Sparrow, Eicos, Electra, Kyverna, UpToDate; R. McBurney, None; M. Kappelman, None; J. Curtis, AbbVie/Abbott, Amgen, ArthritisPower, Aqtual, Bendcare, Bristol-Myers Squibb(BMS), CorEvitas, FASTER, GlaxoSmithKlein(GSK), IlluminationHealth, Janssen, Labcorp, Eli Lilly, Myriad, Novartis, Pfizer, Sanofi, Scipher, Setpoint, UCB, United Rheumatology; M. George, AbbVie, GlaxoSmithKlein(GSK), Chemocentryx.

To cite this abstract in AMA style:

Venkatachalam S, Nowell W, Banerjee S, Gavigan K, Stradford L, Gordon J, Emerich L, Sullivan H, Blazer A, Banbury B, Dronadula V, Weaver K, Degrassi A, Merkel P, McBurney R, Kappelman M, Curtis J, George M. Priority Research Topics for Vaccine Uptake Among Adults with Autoimmune Conditions [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/priority-research-topics-for-vaccine-uptake-among-adults-with-autoimmune-conditions/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/priority-research-topics-for-vaccine-uptake-among-adults-with-autoimmune-conditions/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology